All In Biotech

Drug Trial Radar · NCT04426890

To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous Urticaria

A Double-blind, Randomized, Active-controlled, Parallel Group, Phase 3 Study to Compare Efficacy and Safety of CT-P39 and Xolair in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment

Last checked: Nov 20, 2026Latest source record: Jul 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 634 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

634

Actual

Start

Dec 9, 2020

Primary completion

Oct 21, 2022

Study completion Apr 27, 2023

Sponsor

Lead sponsor
CelltrionIndustry
Sponsor type
Industry
First posted
Jun 11, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Double-blind, Randomized, Active-controlled, Parallel Group, Phase 3 Study to Compare Efficacy and Safety of CT-P39 and Xolair in Patients with Chronic Spontaneous Urticaria Who Remain Symptomatic despite H1 antihistamine Treatment

Conditions

  • Chronic Spontaneous Urticaria

Interventions

  • CT-P39Biological

    Prefilled syringe (PFS) of 1 mL solution

  • EU-approved XolairBiological

    Prefilled syringe (PFS) of 1 mL solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Therapeutic Equivalence Based on Change From Baseline in ISS7 at Week 12 in 300 mg GroupsTime frame: Week 12
  2. Relative Potency of CT-P39 Compared With Xolair Based on Change From Baseline in ISS7 at Week 12Time frame: Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Klinika Ambroziak ESTEDERM

    Warsaw, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.